SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject6/12/2002 4:13:23 PM
From: Czechsinthemail   of 598
 
This morning US Bancorp Piper Jaffray downgraded TLRK citing the discontinuation of T611.

TLRK: downgrade from strong buy to outperform - announced its decision to discontinue development of T611, its anti-cytomegalovirus drug candidate, in the face of evidence that reformulation of the drug would be necessary before proceeding with further clinical trials. Lowering target from $28 to $16

Though we would love for all candidates to work out, T611 wasn't one I was hanging my high hopes on. Actually, I was glad to see management act promptly to cut their losses and redeploy resources in more promising directions.

After getting torpedoed early in the day, the stock rallied and recovered most of the early losses. I think TLRK is a screaming bargain, but I suppose it's also a reminder that as stock prices drop from very low to ridiculously low the screaming can get louder.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News